Rehab Cognitive denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for rehab cognitive are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Cites "Not FDA-Approved" for Cognitive Rehabilitation

Cognitive rehabilitation is a therapeutic service delivered by trained clinicians — it does not involve a drug or device that requires FDA approval in the conventional sense. When UHC issues a "not FDA-approved" or "investigational" denial for cognitive rehabilitation, it typically reflects one of two scenarios: (1) the plan's clinical policy classifies specific cognitive rehabilitation protocols as lacking sufficient evidence under the insurer's internal evidence-rating framework, or (2) a specialized device or software used within the rehabilitation program (such as a computer-based cognitive training tool) has not received FDA clearance as a medical device. Identifying which scenario applies is the first step in your appeal.

## Why This Denial Is Contestable

Professional organizations that establish standards of care for neurological rehabilitation — including those focused on traumatic brain injury, stroke recovery, and acquired cognitive impairment — have published clinical practice guidelines endorsing cognitive rehabilitation as an evidence-based intervention. If UHC's denial is based on an internal coverage policy that conflicts with these professional-society guidelines, that discordance is a strong appeal argument. Peer-reviewed literature and specialty-society position statements are legitimate rebuttal evidence in an external review.

## Federal Appeal Framework

• Internal appeal: Submit within 180 days. Request UHC's full clinical coverage policy and the specific evidence criteria used to classify the service as investigational. Compare those criteria to current specialty-society guidelines.
• External review (ACA §2719): A mandatory option after internal appeal exhaustion, usually within four months of final denial. The IRO applies an independent evidence standard — if the professional literature supports the service, the IRO may overturn UHC's policy-based denial. Turnaround is 45 days standard, 72 hours expedited for urgent cases.
• ERISA §503: Applicable to self-funded employer plans; full-and-fair review rights apply.

## Documentation to Gather

1. UHC's written coverage determination — request the exact policy number and the evidence criteria cited. 2. Treating clinician's letter — explaining that the specific cognitive rehabilitation approach used is consistent with current published guidelines from the relevant specialty organization. 3. Relevant guideline citations — reference the applicable specialty-society guideline (without inventing statistics); your clinician can identify the current version. 4. Patient's clinical records — demonstrating diagnosis, severity, and functional deficits that align with the guideline's recommended indications. 5. Device or software documentation (if applicable) — if the denial targets a specific tool, obtain its FDA clearance status directly from the manufacturer.

## Criteria-Mapping Structure

List each "investigational" finding UHC cited. Opposite each, cite the specific section of the applicable specialty-society guideline (obtained from your clinician) that endorses the intervention for your patient's diagnosis and severity level. Submit copies of the relevant guideline pages as exhibits.